^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    PSB202

    i
    Other names: PSB202, PSB102/PSB107, QLP 31907, PSB 202, PSB-202
    Associations

    News

    Trials
    Company:
    Sound Biologics
    Drug class:
    CD20 inhibitor, CD37 inhibitor
    Related drugs:
    Associations

    News

    Trials
    12d
    A first-in-class bifunctional antibody targeting CD20 and CD37 remodels the immune microenvironment in relapsed or refractory B-cell malignancies. (PubMed, J Hematol Oncol)
    PSB202 may represent a novel dual-targeting strategy that possibly mitigates CD3-related toxicity while promoting cytotoxic immune activation. These findings support further clinical development of PSB202 as an off-the-shelf therapeutic alternative for R/R B-NHL.
    Journal
    |
    IFNG (Interferon, gamma)
    |
    PSB202
    4years
    PSB202 in Patients With Previously Treated-, Relapsed-, Indolent B-Cell Malignancies (clinicaltrials.gov)
    P1a/1b, N=110, Recruiting, Qilu Puget Sound Biotherapeutics (dba Sound Biologics) | Not yet recruiting --> Recruiting
    Enrollment open
    |
    CD20 (Membrane Spanning 4-Domains A1)
    |
    PSB202
    almost5years
    PSB202 in Patients With Previously Treated-, Relapsed-, Indolent B-Cell Malignancies (clinicaltrials.gov)
    P1a/1b, N=110, Not yet recruiting, Qilu Puget Sound Biotherapeutics (dba Sound Biologics)
    Clinical • New P1 trial
    |
    CD20 (Membrane Spanning 4-Domains A1)
    |
    PSB202